United States: Species Are Unpatentable When Prior Art Disclosures Describe The Genus Such That A Person Of Ordinary Skill In The Art Would Be Able To Envision Every Member Of The Class

In AbbVie Inc. v. Mathilda & Terence Kennedy Institute of Rheumatology Trust, No. 13-1545 (Fed. Cir. Aug. 21, 2014), the Federal Circuit affirmed the district court's finding of obviousness-type double patenting. 

The Mathilda and Terence Kennedy Institute of Rheumatology Trust ("Kennedy") is the owner of U.S. Patent Nos. 6,270,766 ("the '766 patent") and 7,846,442 ("the '442 patent"), directed to methods of treating rheumatoid arthritis by co-administering a disease-modifying antirheumatic drug and an antibody.  The '766 patent claims a method of co-administering the Tumor Necrosis Factor Alpha ("TNFα") antibody and methotrexate.  After the '766 patent issued, Kennedy obtained the '442 patent, which contains "method of treatment" claims.  While Kennedy admits that the claims of the '442 patent are encompassed by the '766 patent, the claims of the '442 patent are directed towards a more specific patient group.  The '766 patent previously expired on October 8, 2012, and the '442 patent, which claimed a later priority date than the '766 patent, expires on August 21, 2018.

In 2002, AbbVie Inc. and AbbVie Biotechnology Limited (collectively "AbbVie") licensed the '766 patent and obtained FDA approval to sell Humira, an anti-TNFα antibody, for use either alone or in combination with methotrexate, for the treatment of rheumatoid arthritis.  After the '442 patent issued in 2010, Kennedy demanded that AbbVie pay royalties under the '442 patent in order to continue sales of Humira.  In response, AbbVie sued Kennedy for DJ that the claims of the '442 patent were invalid over the '766 patent under the doctrine of obviousness-type double patenting.  After conducting a bench trial, the district court found that the '442 patent covered the same invention as the '766 patent and was invalid over the claims of the '766 patent for obviousness-type double patenting.  The district court entered a partial final judgment, under Fed. R. Civ. P. 54(b), in favor of AbbVie, and Kennedy appealed.

"Thus, species are unpatentable when prior art disclosures describe the genus containing those species such that a person of ordinary skill in the art would be able to envision every member of the class."  Slip op. at 24.

The Federal Circuit first turned to Kennedy's argument that the statutory and policy rationales for the doctrine of obviousness-type double patenting no longer exist and, thus, the doctrine should be discarded.  Specifically, "[n]ow that the patent term is measured from the earliest claimed priority date, as opposed to the date of issuance, Kennedy contends that the submarine patent problem no longer exists and that the [Uruguay Round Agreements Act] amendment vitiated the policy basis for the doctrine of obviousness-type double patenting."  Slip op. at 11.  The Court, however, disagreed, explaining that Kennedy ignored that the doctrine is also designed to prevent inventors from obtaining a second, later expiring patent on the same invention, which is another "crucial purpose of the doctrine."  Id.  Noting its recent decision in Gilead Sciences, Inc. v. Natco Pharma Ltd., 753 F.3d 1208 (Fed. Cir. 2014), the Court stated, "We now make explicit what was implicit in Gilead:  the doctrine of obviousness-type double patenting continues to apply where two patents that claim the same invention have different expiration dates."  Slip op. at 13.  Indeed, the Court explained, "Kennedy is not entitled to an extra six years of monopoly solely because it filed a separate application unless the two inventions are patentably distinct."  Id.

The Court next addressed whether the doctrine of obviousness-type double patenting applied in the instant case.  Noting that obviousness-type double patenting is a two-step inquiry, the Court first turned to the claim construction of the terms "co-administration" and "active disease" as used in both the '766 and '442 patents. 

As to the term "co-administration," the Court found that, by way of claim construction, Kennedy was attempting to enlarge the scope of the '766 patent while simultaneously narrowing the scope of the '442 patent.  Kennedy took the position that the district court's claim construction of the term "co-administration" erroneously excluded a fourth form of co-administration.  The Court, noting that the specification confirmed the correctness of the district court, found that "[t]he specification never uses the term 'co-administering' to refer to patients who only received the antibody after discontinuing treatment with methotrexate."  Id. at 14.  Indeed, the Court explained, the '766 patent's specification "makes clear that the invention described in the claims is limited to concomitant and adjunctive use."  Id.  Kennedy also argued that the principle of claim differentiation favored its interpretation that claim 8 encompassed embodiments where "single doses of either the antibody or methotrexate are delivered to patients," whereas claim 9 demonstrated that "the only additional limitation is that the anti-TNFα antibody must be administered in a series of doses separated by intervals of days or weeks."  Id. at 18 (citation and internal quotation marks omitted).  The Court did not find Kennedy's argument persuasive because it found that claim 9 does not disclose discontinuation of methotrexate and that the administration of methotrexate is assumed to be ongoing with the single or multiple antibody doses.  Thus, the Federal Circuit found that the specification and claims of the '766 patent supported the district court's correct interpretation of the term "co-administration."

The Court then assessed the district court's claim construction of the term "active disease."  Kennedy contended that the '442 patent provided an explicit definition for the term "active disease."  In support of this contention, Kennedy relied on the prosecution history and the examiner's indefiniteness rejection of the '442 patent for failing to define the term "active disease."  Kennedy provided an explanation that after it pointed to a particular portion of the specification as providing a more specific definition of the term "active disease" during prosecution, the examiner allowed the '442 patent's claims.  AbbVie argued that the particular quoted portion of the specification set forth two definitions and, thus, the inventors could not be viewed as having acted as their own lexicographers.  The Court, however, assumed, without deciding, that Kennedy's proposed construction for "active disease" was correct.  Accordingly, the Court stated that, in the second step of the obviousness-type double patenting inquiry, it "must decide whether a patent that claims to treat a subset of patients with more severe rheumatoid arthritis (the '442 patent) is an obvious variant of a patent that claims treatment of rheumatoid arthritis patients generally (the '766 patent)."  Id. at 21.

Turning to the obviousness inquiry in the second step of its analysis, the Federal Circuit provided a discussion of the law of obviousness-type double patenting and found that "it is clear that a reader of the '766 patent could have easily envisioned a species limited to sicker patients.  The district court was correct in concluding that the species of the '442 patent was not patentably distinct from the genus of the '766 patent."  Id. at 24.  The Court also addressed Kennedy's claim that the species had unexpected results, but found that such a claim was unsupported.  The Court explained that to assess whether the '442 patent yielded unexpected results, the Court had to assess what results were expected at the time the '766 patent application was filed.  The Court concluded that the '442 patent merely claimed the known utility of the '766 patent and did not claim a species with unexpected results.  The Court also acknowledged Kennedy's argument that the '766 patent's disclosures could not be used to determine whether the results of the '442 patent were unexpected because doing so would be tantamount to treating the disclosures of the '766 patent as prior art.  The Court explained that while "a reference patent's specification cannot be used as prior art in an obviousness-type double patenting analysis," "it is also well settled that we may look to a reference patent's disclosures of utility to determine the question of obviousness."  Id. at 26 (citations omitted).  Because the Court determined that the '442 patent did not claim a species manifesting unexpected results, the Court concluded that the '442 patent would have been obvious over the '766 patent.

Accordingly, the Federal Circuit affirmed the district court's finding that the '442 patent was invalid for obviousness-type double patenting in light of the '766 patent and awarded costs to AbbVie.

Judges:  Dyk (author), Wallach, Chen

[Appealed from S.D.N.Y., Judge Crotty]

This article previously appeared in Last Month at the Federal Circuit, September 2014.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
17 Nov 2018, Conference, Washington, DC, United States

Finnegan partner Clare Cornell will present “Covert Trademark Use in the Internet: Licit or Illicit” at the Asian Patent Attorneys Association Conference.

20 Nov 2018, Webinar, Washington, DC, United States

As part of Strafford Publications’ webinar series, Finnegan attorneys Tom Irving, Josh Goldberg, and Cory Bell will analyze Patent Trial and Appeal Board denials and partial denials, offering take-home lessons applicable in

21 Nov 2018, Workshop, London, UK

Finnegan partner Leythem Wall will consider European claim drafting strategy and lead the Chemical Workshop during a two-day course, hosted by Management Forum.

Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions